---
title: Reduce tremor and movement stiffness
nct_id: NCT07572903
phase: NA
status: RECRUITING
sponsor: The First Affiliated Hospital of Anhui Medical University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07572903"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07572903"
last_fetched: "2026-05-12T14:01:56.523Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce tremor and movement stiffness

**Goal (in five words):** Reduce tremor and movement stiffness

**Official Title:** The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease: A Three-arm, Randomized, Double-blind, Parallel-controlled Study

**Trial ID:** [NCT07572903](https://clinicaltrials.gov/study/NCT07572903)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** The First Affiliated Hospital of Anhui Medical University
- **Target Enrollment:** 90 participants
- **Start Date:** 2026-05-06
- **Completion Date:** 2026-07-01
- **Conditions:** Parkinson s Disease
- **Interventions:** Temporal Interference Stimulation
- **Intervention Types:** OTHER

## Summary For Families

The goal is to find out whether temporal interference stimulation can safely reduce Parkinson's motor symptoms like slowness, stiffness, and tremor by modulating the deep brain networks that control movement. Temporal interference is a noninvasive electrical technique that runs two slightly different high-frequency currents through the scalp so they intersect and produce a low-frequency signal deep in the brain, aiming to alter basal ganglia activity without surgery; the trial is randomized, three-arm, double-blind, and tests stimulation as an add-on while participants keep their Parkinson's medications stable. Adults aged 40 and up who meet standard Parkinson's diagnostic criteria, have measurable motor signs (MDS-UPDRS III ≥ 8) and Hoehn and Yahr stage 1,4, and who have had no medication changes for at least 4 weeks can join; people with DBS or prior cranial surgery, ferromagnetic implants, epilepsy, other major neuropsychiatric disorders, recent trial participation, or pregnancy are excluded.

## Eligibility

- **Minimum age:** 40 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Age \>= 40 years;
2. Meet the diagnostic criteria for primary Parkinson's disease (MDS Parkinson's Disease Diagnostic Criteria (2015 Edition));
3. No medication adjustment in the 4 weeks before and during each stimulation;
4. MDS-UPDRS III score \>= 8 points, Hoehn-Yahr score 1-4 points

Exclusion Criteria:

1. Focal brain injury or severe leukoencephalopathy (Fazekas grade 3 or above) on previous head MRI/CT scans;
2. Various secondary Parkinson's syndromes (vascular Parkinson's syndrome, drug-induced Parkinson's syndrome, etc.);
3. Severe craniocerebral trauma, cranial surgery or deep brain stimulation treatment;
4. Ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.;
5. A history of epilepsy, unexplained loss of consciousness, or taking anticonvulsant drugs for epileptic seizures;
6. Diagnosed with neuropsychiatric diseases other than Parkinson's disease;
7. A history of drug abuse or drug use;
8. Participated in any clinical trial in the past 3 months;
9. Pregnant/lactating women or subjects (including men) who plan to have children within 6 months;
10. Other situations that the researchers consider unsuitable for inclusion.
```

## Locations (1)

- The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China _(31.8639, 117.2808)_
  - Junjun Wu — (CONTACT) — +86 0551 62923704 — 2445011385@stu.ahmu.edu.cn

## Central Contacts

- Junjun Wu — (CONTACT) — +86 0551 62923704 — 2445011385@stu.ahmu.edu.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT07572903*  
*HTML version: https://parkinsonspathways.com/trial/NCT07572903*  
*Source data: https://clinicaltrials.gov/study/NCT07572903*